NASDAQ : IMGN

ImmunoGen, Inc.

$31.235 USD

$0.01 (0.02%)

Volume
19.31M
Average Volume
9.19M
Market Capitalization
$8.73B
P/E Ratio
-35.54
Dividend Yield
0.00%
Price Target
$16.00
Year High
$31.25
Year Low
$3.61
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.26
Company Overview

NASDAQ

Mark Joseph Enyedy

Biotechnology

Healthcare

IMGN

277

US

USD

https://www.immunogen.com

781 895 0600

45253H101

0000855654

Liquidity Metrics

0.10

2.26

2.50

2.26

0.00

Sales & Valuation

$108.78M

80.21

50.84

-37.75

-0.91

Profitability

-$0.8789501283360472

-$222.93M

-204.93%

-203.81%

-92.61%

-63.89%

P/E Metrics

-35.54

-0.52

-0.52

Analyst Price Target & Rating

$16.00

$22.00

$6.36

N/A

0/5

22 Analysts

95.22%

Poll Results

About ImmunoGen, Inc. (NASDAQ:IMGN) Stock

ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations ... with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.

Frequently Asked Questions

What is the current ImmunoGen, Inc. (IMGN) stock price?

ImmunoGen, Inc.(NASDAQ:IMGN) stock price is $31.235 in the last trading session. During the trading session, IMGN stock reached the peak price of $31.25 while $3.61 was the lowest point it dropped to. The percentage change in IMGN stock occurred in the recent session was 0.02% while the dollar amount for the price change in IMGN stock was $0.01.

IMGN's industry and sector of operation?

The NASDAQ listed IMGN is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of IMGN?

Theresa G. Wingrove | Senior Vice President of Regulatory Affairs & Quality
Anabel Chan | Head of Investor Relations
Daniel S. Char | Senior Vice President, Chief Legal Officer & Secretary
Mark Joseph Enyedy | President, Chief Executive Officer & Director
Audrey Bergan | Senior Vice President & Chief HR Officer

How many employees does IMGN have?

Number of IMGN employees currently stands at 277. IMGN operates from 830 Winter Street, Waltham, MA 02451-1477, US.

Link for IMGN official website?

Official Website of IMGN is: https://www.immunogen.com

How do I contact IMGN?

IMGN could be contacted at phone #781 895 0600 and can also be accessed through its website. IMGN operates from 830 Winter Street, Waltham, MA 02451-1477, US.

How many shares of IMGN are traded daily?

The average number of IMGN shares traded daily for last 3 months was 9.19M.

What is the market cap of IMGN currently?

The market value of IMGN currently stands at $8.73B with its latest stock price at $31.235